[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @medstudentinvst WaveStrum Life Sciences WaveStrum Life Sciences posts on X about $pasg, $qure, $ntla, $janx the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1948243155779792896/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +14,062% - X Year XXXXXXX +3,818% ### Mentions: X [#](/creator/twitter::1948243155779792896/posts_active)  - X Month XXX +61% - X Months XXX +28,700% - X Year XXX +28,700% ### Followers: XXXXX [#](/creator/twitter::1948243155779792896/followers)  - X Week XXXXX +2.80% - X Month XXXXX +30% ### CreatorRank: undefined [#](/creator/twitter::1948243155779792896/influencer_rank)  ### Social Influence **Social category influence** [cryptocurrencies](/list/cryptocurrencies) [finance](/list/finance) [stocks](/list/stocks) [technology brands](/list/technology-brands) **Social topic influence** [$pasg](/topic/$pasg), [$qure](/topic/$qure), [$ntla](/topic/$ntla), [$janx](/topic/$janx) #8, [$prme](/topic/$prme) #13, [$pepg](/topic/$pepg), [$lly](/topic/$lly), [$nktr](/topic/$nktr), [$abvx](/topic/$abvx), [$pcvx](/topic/$pcvx) **Top accounts mentioned or mentioned by** [@acesobiologics](/creator/undefined) [@geneinvesting](/creator/undefined) [@zhaoweiasu](/creator/undefined) [@grok](/creator/undefined) [@seedy19tron](/creator/undefined) [@neo8634](/creator/undefined) [@cdcgov](/creator/undefined) [@capitalusher](/creator/undefined) [@drjesstaylor](/creator/undefined) [@stmkrs](/creator/undefined) [@cernovich](/creator/undefined) [@monacobiotech](/creator/undefined) [@hall8jack](/creator/undefined) [@blippd](/creator/undefined) [@scamsweeper](/creator/undefined) [@tnguy093](/creator/undefined) [@hannibalspeaks](/creator/undefined) [@adambliv](/creator/undefined) [@endpts](/creator/undefined) [@martinshkreli](/creator/undefined) **Top assets mentioned** [Passage (PASG)](/topic/$pasg) [uniQure N.V. (QURE)](/topic/$qure) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Janux Therapeutics, Inc. Common Stock (JANX)](/topic/$janx) [Eli Lilly and Company (LLY)](/topic/$lly) [Vaxcyte, Inc. Common Stock (PCVX)](/topic/$pcvx) [SuperRare (RARE)](/topic/$rare) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Avidity Biosciences, Inc. Common Stock (RNA)](/topic/$rna) ### Top Social Posts Top posts by engagements in the last XX hours "Daily Update December 2nd 2025. Another punishing day. $JANX dropped the portfolio only about 5.7%. So this shows how much of a hit the big positions of $PRME $NKTR $ABVX $PEPG and $PCVX have taken (and really all of the rest) over the last few days. I added a small bit to $PRME today. The rationale is the same as the last time I added and have reposted that rationale in the second post on this thread. I think the more unfriendly to biotech and chaotic the FDA seems (reversal of FDA alignment with $QURE clinical outcomes studies needed for vaccines not just immunogenicity Pazdur departure" [X Link](https://x.com/medstudentinvst/status/1996024488010342613) 2025-12-03T01:11Z 1067 followers, 4268 engagements "October 22nd 2025 Daily Update Those gene editing stocks sure can be volatile. Large pullback the last coupe of days. Total return actually dipped into the high 60s at one point. If $NTLA $RARE and $PCVX can show good data and $NKTR gets some good news in AA one small upside of that will be a degree of smoothing out in the some of the headline volatility somewhat that is an inherent part of owning a very large position in $PRME. Though in truth the volatility doesn't really matter only the end outcome. Very curious to see what $NKTR has to say about the asthma sub-group in its Nov update" [X Link](https://x.com/medstudentinvst/status/1981091117702730131) 2025-10-22T20:11Z 1063 followers, XXX engagements "Opened position in Passage Bio ( $PASG - $25M market cap). I will write up the short-form thesis when I can. However some interesting parallels to $QURE. This is another HIGH RISK investment and sized accordingly. Treats frontotemporal dementia a notoriously brutal neurodegenerative disease. $PASG lead program targets the GRN subtype. It is comprised of an AAV1 viral vector delivered via injection to the cisterna magna. The GRN subtype is characterized by patients having mutation in the progranulin gene which leads to progranulin haploinsufficiency (50% of normal levels). XX% of GRN mutation" [X Link](https://x.com/medstudentinvst/status/1983983668482994552) 2025-10-30T19:45Z 1063 followers, 2069 engagements "October 30th 2025 Daily Update Explained reasoning behind changes made today in previous posts. X. Closed $CRSP X. Opened $PASG X. Opened another $ABVX position" [X Link](https://x.com/medstudentinvst/status/1983994713037476219) 2025-10-30T20:29Z 1063 followers, 1634 engagements "Needless to say the $QURE news has read through to $PASG. Just so anyone who read my post about investing in it is also aware of this new risk / downside. I plan to continue to hold as I believe its FTD-GRN therapy's profile and current market cap continue to present impressive risk-reward regardless of the ultimate confirmatory trial structure / pathway. Recall that $LLY brough proclaim for $880M plus a CVR and $QURE is still worth $1.89Bn. I also think we're a long way from the conclusion of this $QURE story. However I would be remiss not to acknowledge this and the risk definitely just" [X Link](https://x.com/medstudentinvst/status/1985382743845331319) 2025-11-03T16:25Z 1063 followers, 1074 engagements "The $QURE news is actually less of a read through to $PASG than I initially feared based on this. The FDA appears to be taking issue with a failure by $QURE to define the statistical analysis plan (SAP) before study initiation. While I do think HD patients deserve the right to try with AMT-130 as soon as feasible given the severity of the disease and the lack of therapeutic alternatives and $QURE seems to have a legitimate claim that the FDA is flip-flopping in its stance asking for SAP to be defined ahead of trial initiation is actually quite a reasonable stance in most situations otherwise" [X Link](https://x.com/medstudentinvst/status/1985444565046693954) 2025-11-03T20:30Z 1063 followers, 4151 engagements "This is legitimately impressive and unprecedented efficacy data in ATTR-CM from $NTLA. If it were not for the DILI case recently reported $NTLA's stock would have traded up enormously on this news and I think all the reasonable bears would acknowledge this. If acoramidis and vutrisiran were the only game in town $NTLA might have a shot at a viable path forward on the heels of this data pending the outcome of the DILI investigation. Heart failure is a big deal and obviously kills people. So there is an ethical and rational basis for prescribing a drug that has very rare cases of DILI if it" [X Link](https://x.com/medstudentinvst/status/1988002657043390800) 2025-11-10T21:55Z 1063 followers, 7952 engagements "November 10th 2025 Daily Update. Another day another drop boys and girls. $PRME showing particular weakness. A casualty of the $NTLA blow-up despite what I see as a lack of read-through given the fundamentally different mechanisms. $PEPG also showing some weakness after the very transient uplift post $RNA buyout. $QURE and the rest of the small gene therapy positions continue to struggle post FDA meeting with $QURE" [X Link](https://x.com/medstudentinvst/status/1988017489737879653) 2025-11-10T22:54Z 1063 followers, 2289 engagements "November 12th 2025 Daily Update BIG jump for $PASG off its recent lows. It is of course a high risk investment and may remain volatile through the 1H 2026 updates. However I continue to believe the risk-reward profile here is extremely strong. To that point $LLY paid $1.04Bn (inclusive of a CVR) for Prevail and its FTD-GRN therapy back in 2021 both $PASG and $LLY are in Phase X / X (though should note Prevail also had a PD asset in clinical development) and my view is that $PASG has shown more compelling data to date on both efficacy and safety. $PASG is still trading under $30M at the" [X Link](https://x.com/medstudentinvst/status/1988722338196787622) 2025-11-12T21:35Z 1064 followers, 1070 engagements "This is a very good post by Adam. I'd like to add a couple of thoughts on AMT-130 and speak to the applicability of some of these concepts to $PASG and alpha-synuclein targeted therapies in Parkinson's Disease. First there may be an issue with tominersin in addition to the ones Adam spoke to. The huntingtin protein is absolutely essential to neuronal (and glial for that matter) function and health. This is well described in both human beings and animal models. In fact human beings born with compound heterozygous mutations in the HTT gene (one mutated copy from each parent) experience a rare" [X Link](https://x.com/medstudentinvst/status/1990608958600380685) 2025-11-18T02:32Z 1064 followers, 12.7K engagements "Regarding $LLY theyre in Phase I and havent shown any human data at all yet nor substantive preclinical data. If youre concerned about $PASG not publishing ISF PGRN concentrations (just vgs) you should be particularly concerned about $LLY / Prevail in that respect. As an additional point re human data it is notable that we know of no living human with a high-confidence LoF alpha-synuclein variant which precludes the kind of MR studies that have shown benefit in most other siRNA contexts. Further studies show that in active PD outcomes are worse for patients who have lower levels of monomeric" [X Link](https://x.com/medstudentinvst/status/1990767168238051342) 2025-11-18T13:00Z 1064 followers, XXX engagements "You seem to believe a PBFT02 failure is fait accompli though the basis for that appears to center on the fact that $PASG has not reported PGRN ISF concentrations that appears you presume they are hiding. It would be rather strange they would take the low-dose cohort forward if there is some unreleased internal data suggesting that is an issue. They will start to report more fulsome data in 1H 2026 so we will see how that unfolds. The data from the new cohort of patients they dosed very early in disease course will be especially interesting. Whilst I fully acknowledge the high risk nature of" [X Link](https://x.com/medstudentinvst/status/1990797447321337935) 2025-11-18T15:01Z 1064 followers, XXX engagements "November 28th 2025 Daily Update $PEPG really having a moment. Good to get back into the 60's after the $NTLA news and the subsequent overhang on the gene editing sector" [X Link](https://x.com/medstudentinvst/status/1994562451787190648) 2025-11-29T00:22Z 1063 followers, 2775 engagements "Increased $JANX to about XXX% of the portfolio. Done adding for today" [X Link](https://x.com/medstudentinvst/status/1995587763295715372) 2025-12-01T20:16Z 1067 followers, 5806 engagements "Further exited the $RARE position to add to $JANX. Full breakdown posted tonight. However want to publicly disclose for accountability given post-market update" [X Link](https://x.com/medstudentinvst/status/1995527227501314376) 2025-12-01T16:15Z 1067 followers, 5206 engagements "December 4th 2025 Daily Update Pleased thus far with the add to $PRME in that XXXX range for the reasons described a few days back. Reclassified the $PRME buy stages a bit as technically there were X buys in that first stage and there are now X in the second buy stage and don't want to do the whole reformat. Made some rather large additional moves today. Super busy week so don't have time to go through the full rationales now. Will try to do this weekend. I closed the $PCVX position for a XX% gain and put all of it towards $ABVX. I think $PCVX will navigate the vaccine turmoil just fine in" [X Link](https://x.com/medstudentinvst/status/1996768766680609174) 2025-12-05T02:29Z 1067 followers, 1583 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@medstudentinvst WaveStrum Life Sciences
WaveStrum Life Sciences posts on X about $pasg, $qure, $ntla, $janx the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +14,062%
- X Year XXXXXXX +3,818%
Mentions: X #
- X Month XXX +61%
- X Months XXX +28,700%
- X Year XXX +28,700%
Followers: XXXXX #
- X Week XXXXX +2.80%
- X Month XXXXX +30%
CreatorRank: undefined #
Social Influence
Social category influence cryptocurrencies finance stocks technology brands
Social topic influence $pasg, $qure, $ntla, $janx #8, $prme #13, $pepg, $lly, $nktr, $abvx, $pcvx
Top accounts mentioned or mentioned by @acesobiologics @geneinvesting @zhaoweiasu @grok @seedy19tron @neo8634 @cdcgov @capitalusher @drjesstaylor @stmkrs @cernovich @monacobiotech @hall8jack @blippd @scamsweeper @tnguy093 @hannibalspeaks @adambliv @endpts @martinshkreli
Top assets mentioned Passage (PASG) uniQure N.V. (QURE) Intellia Therapeutics, Inc (NTLA) Janux Therapeutics, Inc. Common Stock (JANX) Eli Lilly and Company (LLY) Vaxcyte, Inc. Common Stock (PCVX) SuperRare (RARE) CRISPR Therapeutics AG (CRSP) Avidity Biosciences, Inc. Common Stock (RNA)
Top Social Posts
Top posts by engagements in the last XX hours
"Daily Update December 2nd 2025. Another punishing day. $JANX dropped the portfolio only about 5.7%. So this shows how much of a hit the big positions of $PRME $NKTR $ABVX $PEPG and $PCVX have taken (and really all of the rest) over the last few days. I added a small bit to $PRME today. The rationale is the same as the last time I added and have reposted that rationale in the second post on this thread. I think the more unfriendly to biotech and chaotic the FDA seems (reversal of FDA alignment with $QURE clinical outcomes studies needed for vaccines not just immunogenicity Pazdur departure"
X Link 2025-12-03T01:11Z 1067 followers, 4268 engagements
"October 22nd 2025 Daily Update Those gene editing stocks sure can be volatile. Large pullback the last coupe of days. Total return actually dipped into the high 60s at one point. If $NTLA $RARE and $PCVX can show good data and $NKTR gets some good news in AA one small upside of that will be a degree of smoothing out in the some of the headline volatility somewhat that is an inherent part of owning a very large position in $PRME. Though in truth the volatility doesn't really matter only the end outcome. Very curious to see what $NKTR has to say about the asthma sub-group in its Nov update"
X Link 2025-10-22T20:11Z 1063 followers, XXX engagements
"Opened position in Passage Bio ( $PASG - $25M market cap). I will write up the short-form thesis when I can. However some interesting parallels to $QURE. This is another HIGH RISK investment and sized accordingly. Treats frontotemporal dementia a notoriously brutal neurodegenerative disease. $PASG lead program targets the GRN subtype. It is comprised of an AAV1 viral vector delivered via injection to the cisterna magna. The GRN subtype is characterized by patients having mutation in the progranulin gene which leads to progranulin haploinsufficiency (50% of normal levels). XX% of GRN mutation"
X Link 2025-10-30T19:45Z 1063 followers, 2069 engagements
"October 30th 2025 Daily Update Explained reasoning behind changes made today in previous posts. X. Closed $CRSP X. Opened $PASG X. Opened another $ABVX position"
X Link 2025-10-30T20:29Z 1063 followers, 1634 engagements
"Needless to say the $QURE news has read through to $PASG. Just so anyone who read my post about investing in it is also aware of this new risk / downside. I plan to continue to hold as I believe its FTD-GRN therapy's profile and current market cap continue to present impressive risk-reward regardless of the ultimate confirmatory trial structure / pathway. Recall that $LLY brough proclaim for $880M plus a CVR and $QURE is still worth $1.89Bn. I also think we're a long way from the conclusion of this $QURE story. However I would be remiss not to acknowledge this and the risk definitely just"
X Link 2025-11-03T16:25Z 1063 followers, 1074 engagements
"The $QURE news is actually less of a read through to $PASG than I initially feared based on this. The FDA appears to be taking issue with a failure by $QURE to define the statistical analysis plan (SAP) before study initiation. While I do think HD patients deserve the right to try with AMT-130 as soon as feasible given the severity of the disease and the lack of therapeutic alternatives and $QURE seems to have a legitimate claim that the FDA is flip-flopping in its stance asking for SAP to be defined ahead of trial initiation is actually quite a reasonable stance in most situations otherwise"
X Link 2025-11-03T20:30Z 1063 followers, 4151 engagements
"This is legitimately impressive and unprecedented efficacy data in ATTR-CM from $NTLA. If it were not for the DILI case recently reported $NTLA's stock would have traded up enormously on this news and I think all the reasonable bears would acknowledge this. If acoramidis and vutrisiran were the only game in town $NTLA might have a shot at a viable path forward on the heels of this data pending the outcome of the DILI investigation. Heart failure is a big deal and obviously kills people. So there is an ethical and rational basis for prescribing a drug that has very rare cases of DILI if it"
X Link 2025-11-10T21:55Z 1063 followers, 7952 engagements
"November 10th 2025 Daily Update. Another day another drop boys and girls. $PRME showing particular weakness. A casualty of the $NTLA blow-up despite what I see as a lack of read-through given the fundamentally different mechanisms. $PEPG also showing some weakness after the very transient uplift post $RNA buyout. $QURE and the rest of the small gene therapy positions continue to struggle post FDA meeting with $QURE"
X Link 2025-11-10T22:54Z 1063 followers, 2289 engagements
"November 12th 2025 Daily Update BIG jump for $PASG off its recent lows. It is of course a high risk investment and may remain volatile through the 1H 2026 updates. However I continue to believe the risk-reward profile here is extremely strong. To that point $LLY paid $1.04Bn (inclusive of a CVR) for Prevail and its FTD-GRN therapy back in 2021 both $PASG and $LLY are in Phase X / X (though should note Prevail also had a PD asset in clinical development) and my view is that $PASG has shown more compelling data to date on both efficacy and safety. $PASG is still trading under $30M at the"
X Link 2025-11-12T21:35Z 1064 followers, 1070 engagements
"This is a very good post by Adam. I'd like to add a couple of thoughts on AMT-130 and speak to the applicability of some of these concepts to $PASG and alpha-synuclein targeted therapies in Parkinson's Disease. First there may be an issue with tominersin in addition to the ones Adam spoke to. The huntingtin protein is absolutely essential to neuronal (and glial for that matter) function and health. This is well described in both human beings and animal models. In fact human beings born with compound heterozygous mutations in the HTT gene (one mutated copy from each parent) experience a rare"
X Link 2025-11-18T02:32Z 1064 followers, 12.7K engagements
"Regarding $LLY theyre in Phase I and havent shown any human data at all yet nor substantive preclinical data. If youre concerned about $PASG not publishing ISF PGRN concentrations (just vgs) you should be particularly concerned about $LLY / Prevail in that respect. As an additional point re human data it is notable that we know of no living human with a high-confidence LoF alpha-synuclein variant which precludes the kind of MR studies that have shown benefit in most other siRNA contexts. Further studies show that in active PD outcomes are worse for patients who have lower levels of monomeric"
X Link 2025-11-18T13:00Z 1064 followers, XXX engagements
"You seem to believe a PBFT02 failure is fait accompli though the basis for that appears to center on the fact that $PASG has not reported PGRN ISF concentrations that appears you presume they are hiding. It would be rather strange they would take the low-dose cohort forward if there is some unreleased internal data suggesting that is an issue. They will start to report more fulsome data in 1H 2026 so we will see how that unfolds. The data from the new cohort of patients they dosed very early in disease course will be especially interesting. Whilst I fully acknowledge the high risk nature of"
X Link 2025-11-18T15:01Z 1064 followers, XXX engagements
"November 28th 2025 Daily Update $PEPG really having a moment. Good to get back into the 60's after the $NTLA news and the subsequent overhang on the gene editing sector"
X Link 2025-11-29T00:22Z 1063 followers, 2775 engagements
"Increased $JANX to about XXX% of the portfolio. Done adding for today"
X Link 2025-12-01T20:16Z 1067 followers, 5806 engagements
"Further exited the $RARE position to add to $JANX. Full breakdown posted tonight. However want to publicly disclose for accountability given post-market update"
X Link 2025-12-01T16:15Z 1067 followers, 5206 engagements
"December 4th 2025 Daily Update Pleased thus far with the add to $PRME in that XXXX range for the reasons described a few days back. Reclassified the $PRME buy stages a bit as technically there were X buys in that first stage and there are now X in the second buy stage and don't want to do the whole reformat. Made some rather large additional moves today. Super busy week so don't have time to go through the full rationales now. Will try to do this weekend. I closed the $PCVX position for a XX% gain and put all of it towards $ABVX. I think $PCVX will navigate the vaccine turmoil just fine in"
X Link 2025-12-05T02:29Z 1067 followers, 1583 engagements